In conclusion, our genetic analysis predicts that in a broader dyslipidaemic patient population, therapies aimed at decreasing plasma ANGPTL3, ANGPTL4, or APOC3 levels will be effective in preventing CAD without raising specific safety concerns. This evidence concerns the gene APOC3 and coronary artery disorder.